Navigation Links
Study identifies a likely key driver of colorectal cancer development and progression
Date:4/14/2014

COLUMBUS, Ohio A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression.

The study of microRNA-135b (miR-135b) in two animal models and human tumors was published in the journal Cancer Cell and was led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at the University of Glasgow in the United Kingdom.

The researchers demonstrate that miR-135b is present at abnormally high levels in both mouse and human colorectal (CRC) tumors. The overexpression can be induced by the mutations in either well-known oncogenes or tumor-suppressor genes that frequently occur in CRC, the researchers say.

"We found that miR-135b is up-regulated in both sporadic and inflammatory bowel disease-associated colorectal cancer, and that its up-regulation is associated with tumor stage and poor clinical outcome," says principal investigator Carlo M. Croce, MD, chair of molecular virology, immunology and medical genetics, and director of Human Cancer Genetics at Ohio State and the OSUCCC James.

"Our findings provide proof-of-principle that anti-miR-135b has significant therapeutic potential in colorectal cancer treatment," says Croce, who is also the John W. Wolfe Chair in Human Cancer Genetics.

For this study, Croce and his collaborators used a CRC mouse model based on loss of a tumor suppressor and a model based on inflammation and oncogene activation; human tumors from a cohort of sporadic CRC and inflammatory-bowel-disease associated CRC; human and animal cell lines and data from The Cancer Genome Atlas.

Key findings included:

  • MiR-135b up-regulation occurs in both sporadic and inflammatory bowel disease-associated CRC, and it is associated with tumor stage and poor clinical outcome;
  • Loss of the APC gene, deregulation of the PTEN/PI3K pathway and over-expression of the SRC oncogene all trigger miR-135b over-expression;
  • Artificial miR-135b over-expression increases cell proliferation and reduces apoptosis, as occurs with APC loss or PI3K or SRC activation.
  • Delivering anti-miR-135b in an inflammation-related CRC mouse model affected proliferation and apoptosis, resulting in reduced tumor number and size.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related medicine news :

1. Study gives high marks to NC Pre-K program
2. Proteomics International biomarker study closer to a CDx test for diabetic kidney disease
3. Study links domestic abuse to mental health problems in new mothers
4. Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds
5. Lipid levels during prenatal brain development impact autism: York U study
6. ED dental care treatment raises access, cost issues for policymakers, Rutgers study finds
7. $2.5 million Defense Department grant funds gene therapy study for Lou Gehrigs disease
8. Study finds link between childs obesity and cognitive function
9. Study reveals animal research bias in experimentation oversight committee membership
10. Fruitfly study: Epilepsy drug target implications for sleep disruption in brain disorders
11. Obesity primes the colon for cancer, according to NIH study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
(Date:3/29/2017)... Mich. (PRWEB) , ... March ... ... and Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, ... supplement industry. The organization, which plans to publish the first ANSI-approved GMP ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... Los Angeles, CA (PRWEB) , ... March 28, 2017 , ... ... “wake-up call” asking the American public to take the Diabetes Risk Test to find ... the event, the Los Angeles World Airports will light up the evening sky by ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... leader in accelerated orthodontics, OrthoAccel ® Technologies, Inc. ... Manal Ibrahim , Kenji Ojima , Ivan ... microlecture presenters at the AcceleDent ® booth (#3037) ... Session, April 21-25, 2017. Orthodontists and their staff are ... a.m. On the opening morning of AAO exhibitions, Sat., ...
(Date:3/29/2017)... According to a new market research report "Medical Radiation Detection, Monitoring & ... Products (Personal Dosimeters, OSL, Badges), Safety (Apron, Shields, Face Mask, Gloves), End ... to reach USD 1,215.4 Million by 2021 from USD 887.0 Million in ... Continue Reading ... ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global lifestyle drugs market to grow ... The report, Global Lifestyle Drugs Market 2017-2021, has been prepared ... The report covers the market landscape and its growth prospects over ...
Breaking Medicine Technology: